Bio-Rad Laboratories Class A
504 hedge funds and large institutions have $9.2B invested in Bio-Rad Laboratories Class A in 2023 Q1 according to their latest regulatory filings, with 80 funds opening new positions, 196 increasing their positions, 160 reducing their positions, and 39 closing their positions.
105% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 39
86% more funds holding in top 10
Funds holding in top 10: 7 → 13 (+6)
23% more repeat investments, than reductions
Existing positions increased: 196 | Existing positions reduced: 160
15% more capital invested
Capital invested by funds: $8.03B → $9.2B (+$1.17B)
7% more funds holding
Funds holding: 470 → 504 (+34)
1.29% more ownership
Funds ownership: 77.04% → 78.33% (+1.3%)
30% less call options, than puts
Call options by funds: $40.2M | Put options by funds: $57.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Los Angeles Capital Management
Los Angeles,
California
|
+$86.5M |
| 2 |
EC
Eminence Capital
New York
|
+$78.7M |
| 3 |
Millennium Management
New York
|
+$66.6M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$60.5M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$53.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Amundi
Paris,
France
|
-$71.5M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$46.1M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$39.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$36.9M |
| 5 |
A
AustralianSuper
Melbourne,
Australia
|
-$32.2M |
BIO Hedge Fund Activity: Q1 2023 in Review
504 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q1 2023, worth a combined $9.2B — up 15% from $8.03B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new BIO positions and 39 closed out — a net gain of 41 holders — while 196 added to existing stakes and 160 trimmed.
The largest buyer was Los Angeles Capital Management, opening a new position worth an estimated $86.5M. The largest seller was Amundi, cutting an estimated $71.5M.
- 504 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q1 2023, up from 470 in Q4 2022.
- Funds reported $9.2B of Bio-Rad Laboratories Class A stock for Q1 2023, up 15% quarter-over-quarter.
- 80 funds opened new Bio-Rad Laboratories Class A positions in Q1 2023 and 39 closed out, a net change of +41 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q1 2023 was Los Angeles Capital Management, an estimated $86.5M added.
- The largest Bio-Rad Laboratories Class A seller in Q1 2023 was Amundi, an estimated $71.5M sold.
Based on aggregated 13F filings for Q1 2023.